The CEO of Novo Nordisk plans to blame drug middlemen for the high cost of popular diabetes and weight loss drugs Ozempic and Wegovy during a Senate hearing Wednesday ...

Novo Nordisk’s CEO testified Tuesday that the company has little control over what patients pay for its blockbuster diabetes and weight-loss drugs as skeptical senators criticized the Danish ...

Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program ...

Sept 23 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's ...

After circling Novo Nordisk and its high GLP-1 drug prices for months, Sen. Bernie Sanders, I-Vermont, and the Senate Health, Education, Labor and Pensions (HELP) committee will soon get their ...

The news item from Novo Nordisk that was so impactful was the readout from a clinical trial of monlunabant, an investigational treatment it's testing for obesity. In a phase 2a clinical trial ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Sept 17 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations ...

After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. Novo’s semaglutide cut the ...

In today’s hearing, however, Senator Bernie Sanders put the focus on the maker of the medicine, Novo Nordisk. What’s more he said those same three PBM firms had committed to him that they ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...